Return to homepagePandemic Pact

to support the global COVID-19 outbreak response by testing of selected compounds in the 3D in vitro human respiratory tissues, MucilAir'Ñ¢

Grant number: INV-016776

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020

  • Known Financial Commitments (USD)

    $1,767,102

  • Funder

    Gates Foundation

  • Research Location

    Switzerland

  • Lead Research Institution

    Epithelix Sàrl

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

N/A

2 Publications linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

Multidrug Combinations against SARS-CoV-2 Using GS-441524 or Ivermectin with Molnupiravir and/or Nirmatrelvir in Reconstituted Human Nasal Airway Epithelia.

Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro.